REGENXBIO Inc. (RGNX) Financials

RGNX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 341.9 million 320.8 million
Dec. 31, 2025 453.0 million 350.3 million
Sept. 30, 2025 525.2 million 363.8 million
June 30, 2025 581.0 million 367.3 million

RGNX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -77.4 million 8.6 million
Dec. 31, 2025 -52.8 million 8.4 million
Sept. 30, 2025 -56.5 million 9.0 million
June 30, 2025 -49.7 million 8.7 million

RGNX Net Income

No data available :(

RGNX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 150.5 million 63.2 million 71.1 million
Dec. 31, 2025 230.1 million 147.4 million 65.2 million
Sept. 30, 2025 274.2 million 149.9 million 67.4 million
June 30, 2025 323.3 million - 77.7 million

RGNX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 52.4 million
Dec. 31, 2025 51.8 million
Sept. 30, 2025 51.7 million
June 30, 2025 51.5 million

RGNX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 1.2 million 57.3 million 21.3 million -
Dec. 31, 2025 508000 59.6 million 22.4 million -
Sept. 30, 2025 491000 56.1 million 20.3 million -
June 30, 2025 391000 55.6 million 19.9 million -

RGNX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 6.4 million 11.1 million
Dec. 31, 2025 30.3 million 5.9 million
Sept. 30, 2025 29.7 million 61.8 million
June 30, 2025 21.4 million 9.1 million

RGNX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

RGNX

Price: $9.73

52 week price:
5.46
16.19

Earnings Per Share: -5.60 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 295200

Ebitda: -20.6 million

Market Capitalization: 766.7 million

Links: